Novel Enterobacter Lineage as Leading Cause of Nosocomial Outbreak Involving Carbapenemase-Producing Strains
Racha Beyrouthy, Marion Barets, Elodie Marion, Cédric Dananché, Olivier Dauwalder, Frédéric Robin, Lauraine Gauthier, Agnès Jousset, Laurent Dortet, François Guérin, Thomas Bénet, Pierre Cassier, Philippe Vanhems
1, and Richard Bonnet
1
Author affiliations: Centre Hospitalier Universitaire, Clermont-Ferrand, France (R. Beyrouthy, F. Robin, R. Bonnet); Centre National de Référence de la Résistance aux Antibiotiques, Clermont-Ferrand (R. Beyrouthy, F. Robin, R. Bonnet); Université Clermont Auvergne, Clermont-Ferrand (R. Beyrouthy, F. Robin, R. Bonnet); Institut National de la Santé et de la Recherche Médicale, Clermont-Ferrand (R. Beyrouthy, F. Robin, R. Bonnet); Institut National de la Recherche Agronomique, Clermont-Ferrand (R. Beyrouthy, F. Robin, R. Bonnet); Hôpital Édouard Herriot, Hospices Civils de Lyon, Lyon, France (M. Barets, E. Marion, C. Dananché, T. Bénet, P. Cassier, P. Vanhems); Groupement Hospitalier Est, Hospices Civils de Lyon, Lyon (O. Dauwalder); Centre International de Recherche en Infectiologie, Lyon (O. Dauwalder, T. Bénet, P. Vanhems),; Centre Hospitalier Universitaire Bicêtre, Paris, France (L. Gauthier, A. Jousset, L. Dortet); Centre National de Référence Associé de la Résistance aux Antibiotiques, Paris (L. Gauthier, A. Jousset, L. Dortet); Centre Hospitalier Universitaire, Caen, France (F. Guérin)
Main Article
Table 2
Key features of clinical VIM-4–producing Enterobacter cloacae complex isolates in nosocomial outbreak involving carbapenamase-producing strains, Lyon, France, January 12, 2014–December 31, 2015*
Isolate
|
Species
|
ST
|
hsp60 cluster
(phylogenome)
|
Size of assembled genomes, bp
|
MICs, mg/L |
ETP
|
IPM
|
MEM
|
CAZ
|
CTX
|
FEP
|
ATM
|
C45 |
E. cloacae complex |
873 |
NA (S) |
5,290,194 |
2 |
2 |
1 |
32 |
>32 |
4 |
4 |
C46 |
E. cloacae complex |
873 |
NA (S) |
5,257,311 |
2 |
1 |
0.5 |
24 |
>32 |
2 |
4 |
C48 |
E. cloacae complex |
873 |
NA (S) |
5,260,873 |
2 |
2 |
0.5 |
24 |
>32 |
2 |
4 |
C310 |
E. cloacae complex |
873 |
NA (S) |
5,254,482 |
2 |
2 |
1 |
24 |
>32 |
2 |
2 |
E14 |
E. cloacae complex |
873 |
NA (S) |
5,251,662 |
2 |
2 |
1 |
32 |
>32 |
4 |
4 |
E16 |
E. cloacae complex |
873 |
NA (S) |
5,250,845 |
2 |
2 |
1 |
32 |
>32 |
4 |
4 |
C47 |
E. cloacae cluster III |
118 |
III (D) |
5,083,854 |
2 |
2 |
0.5 |
16 |
>32 |
2 |
0.25 |
C308 |
E. cloacae cluster III |
118 |
III (D) |
4,998,377 |
2 |
1 |
0.25 |
32 |
>32 |
2 |
0.5 |
C309
|
E. hormaechei steigerwaltii
|
110
|
VIII (B)
|
5,200,769
|
4
|
2
|
0.5
|
96
|
>32
|
8
|
32
|
*ATM, aztreonam; CAZ, ceftazidime; CTX, cefotaxime; ETP, ertapenem; FEP; IPM, imipenem; MEM, meropenem; NA, not applicable; ST, sequence type. |
Main Article
Page created: July 18, 2018
Page updated: July 18, 2018
Page reviewed: July 18, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.